In refractory Hodgkin disease and MM, an mTOR inhibitor was introduced in addition to pioglitazone, metronomic low-dose chemotherapy, and COX-2 inhibitor; in Hodgkin lymphoma, a glucocorticoid was used, additionally. The gene discussed is PTGS2; the disease is Hodgkins lymphoma.